- Home
- HCTI vs IMNN Comparison
HCTI vs IMNN Comparison
Compare HCTI & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCTI | IMNN |
|---|---|---|
| Founded | 2020 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5M | 12.9M |
| IPO Year | 2021 | 1985 |
Fundamental Metrics
Financial Performance| Metric | HCTI | IMNN |
|---|---|---|
| Price | $0.57 | $4.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $182.61 |
| AVG Volume (30 Days) | ★ 686.7K | 72.3K |
| Earning Date | 11-13-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,942,000.00 | N/A |
| Revenue This Year | $47.01 | N/A |
| Revenue Next Year | $44.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.49 | $2.99 |
| 52 Week High | $435.75 | $41.22 |
Technical Indicators
Market Signals| Indicator | HCTI | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 20.94 | 53.31 |
| Support Level | $0.49 | $2.99 |
| Resistance Level | $2.53 | $4.20 |
| Average True Range (ATR) | 0.19 | 0.32 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 4.57 | 82.65 |
Price Performance
Historical ComparisonAbout HCTI Healthcare Triangle Inc.
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their effort to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Platform Services.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).